Abstract Radioresistance is a frustrating obstacle for patients with colorectal cancers (CRCs) undergoing radiotherapy.
Introduction
Colorectal cancer (CRCs) is the third largest killer among all kinds of malignant tumors in the USA [1] . The management of locally advanced CRCs requires a multidisciplinary effort, with surgical resection remaining the therapeutic cornerstone, and radiotherapy and neoadjuvant chemotherapy clearly improving long-term outcomes [2] . In Asian countries, most CRC patients are diagnosed or detected at a late stage with local invasion or metastasis. Moreover, some patients with tumor recurrence lose the chance of surgical intervention, and hence radiotherapy will be the last straw for them. However, as a two-edged sword, radiotherapy also leads to some serious side effects, which forces many cancer patients to stop receiving radiotherapy. Therefore, there is an urgent need to find an effective radiosensitizer to reduce the dose of radiotherapy without decreasing the tumor growth inhibiting effect.
Honokiol is an active compound purified from magnolia, and recent studies have demonstrated anti-inflammatory, antiangiogenic, antioxidative, and anticancer properties for the compound both in vitro and in preclinical models [3••] . It targets multiple signaling pathways, including angiogenesis, nuclear factor kappa B [4], signal transducer and activator of transcription (STAT) 3, epidermal growth factor receptor, and mammalian target of rapamycin [5] , all of which have great relevance during cancer initiation and progression. Furthermore, the pharmacokinetic profile of honokiol has revealed a desirable spectrum of bioavailability after intravenous administration in animal models [3••] .
From in vitro and in vivo studies, honokiol has demonstrated the ability to inhibit growth and induce apoptosis in a variety of cancer cell lines. Furthermore, our study showed that honokiol can also enhance the sensitivity of colon cancer cells to radiation, which can safely reduce the dose of radiation without affecting the outcome [6••]. In addition, our studies found that honokiol in combination with irradiation can even enhance the sensitivity of colon cancer stem cells to ionizing radiation. It may target the stem cells by inhibiting the γ-secretase complex and the Notch signaling pathway [7••] . These findings shed light on the radiosensitizing effect of honokiol on CRCs.
It is well known that carcinogenesis is a multiple signal pathway process, and is still a complicate puzzle. It involves gene mutations, apoptosis escape and aberrant angiogenesis, and other pathways. Here, we have reviewed previous studies on honokiol's antitumor effects and hope to identify some possible mechanisms.
Honokiol and Cell Cycle Arrest
The cell cycle is an ordered procession whereby the initiation of every event depends on the completion of the former event. Cells in different phases exhibit differing levels of radiosensitivity [8] . Many studies have demonstrated radiation-induced cell cycle delay [9, 10] . Furthermore, cells in different phases of the cell cycle show diverse responses to radiation. In general, cells are most radiosensitive in M and G 2 phases and are most radioresistant in S phase, whereas for cells with a long cycle time, there is another peak of resistance in early G 1 phase [11•] .
Chemotherapeutic agents which can cause cell cycle arrest may increase the radiosensitivity of different cancer cells to radiotherapy. Our study showed that honokiol can lead to G 0 / G 1 phase arrest of colon cancer cells. Moreover, when cells were treated with honokiol in combination with radiation, there was significant enhancement in their sensitivity to radiation. Hahm et al. [12] showed that honokiol induces cell cycle arrest of PC-3 and LNCaP human prostate cancer cells in a concentration-and time-dependent manner. The cells were mostly arrested in G 0 -G 1 phase, with a decrease in the protein levels of cyclin D1, cyclin-dependent kinase 4 (Cdk4), cyclin-dependent kinase 6, and/or cyclin E. In addition, there was suppression of complex formation between cyclin D1 and Cdk4 as revealed by immunoprecipitation using anti-cyclin D1 antibody followed by immunoblotting for Cdk4 protein [12] .
According to the studies on honokiol's antitumor effect and the relation between the cell cycle and tumor radiosensitization, it is suggested that honokiol may have a radiosensitizing effect on malignant tumors, including colon cancer, by affecting the cell cycle.
Honokiol and Angiogenesis
It is widely accepted that for solid tumors angiogenesis is necessary for them to grow to a diameter over 2 mm to obtain oxygen and nutrients [13] . Angiogenesis is a process of new vasculature formation. It can not only provide sufficient oxygen and nutrients, but can also ensure that there is homeostasis inside and around tumors, which can support autonomous tumor proliferation [14•] . Angiogenesis also plays a vital role during the process of metastasis. New blood vessels are considered to be essential for the delivery of nutrients and oxygen to the tumor microenvironment. Moreover, new blood vessels seem to be critical by providing a route for metastasis.
It is well known that radiation can lead to DNA damage; consequently, cells activate a phosphorylation-based signaling cascade known as the DNA damage response [15] . DNA lesions are recognized by a network of sensor and mediator factors that result in the rapid recruitment of ataxia telangiectasia mutated (ATM) and ATM-Rad3 related to the site of DNA damage [16] . These kinases activate Chk1 and Chk2 [17] , which ultimately activate numerous cellular pathways, including cell cycle arrest [18] . Truman et al. [19] studied the relationship between radiation-induced apoptosis and the downregulation of ATM protein. They found that downregulation of ATM protein can sensitize human prostate cancer cells to radiation-induced apoptosis [19] .
Vascular endothelial growth factor (VEGF) is an endothelialstimulating factor of great importance to angiogenesis. In an in vivo study, Gupta et al. [20] discovered that inhibition of VEGF could significantly reduce the sensitivity of rastransformed murine fibrosarcoma cell lines to radiotherapy. Furthermore, the mechanisms behind the relationship between angiogenesis and radiosensitization aroused a cascade of studies. As a result, hypoxia-inducible factor 1 (HIF-1) was identified as a key regulator [21] . Kang et al. [22] showed that HIF-1α overexpression enhances tumor angiogenesis via upregulation of VEGF and other hypoxia-inducible angiogenic factors, which leads to a more aggressive tumor phenotype. On the other hand, trichostatin A was found to reduce both messenger RNA and protein levels of HIF-1α. In addition, VEGF expression was also reduced significantly. Together, these data suggest that trichostatin A could be a promising drug targeting tumor angiogenesis via inhibition of HIF-1α and VEGF expression.
Radiation-induced hypoxia can trigger tumor radioresistance by activating angiogenesis through HIF-1-regulated cytokines [23] . A study by Magnon et al. [23] indicated that the use of angiogenic inhibitors, such as canstatin, combined with targeted radioiodide therapy enhances tumor cell apoptosis. This postulates that HIF-1 may display a radiosensitizing activity that is highly dependent on the treatment modality by regulating key apoptotic molecular pathways.
As mentioned above, tumor angiogenesis is necessary for radioresistance. Conversely, radiation can also promote the process of angiogenesis. In a study by Sofia Vala et al. [24•] , it was found that low-dose ionizing radiation not only induced VEGF production in hypoxia-mimicking conditions, but also induced rapid phosphorylation of several endothelial cell proteins, including VEGF receptor 2. By activating the receptor, low-dose ionizing radiation enhanced endothelial cell migration and prevented endothelial cell death that was promoted by an antiangiogenic drug, bevacizumab.
HIF-1 activity, in turn, induces the expression of angiogenic growth factors such as VEGF and fibroblast growth factor 2 (FGF-2). These cytokines promote endothelial survival pathways and counteract radiation-induced apoptosis in both tumor cells and endothelial cells. To circumvent this radiationinduced protective angiogenic response, one promising therapeutic approach may be to combine angiogenesis inhibition with radiotherapy [25] . During hypoxia, an intricate balance exists between factors that induce and those that counteract apoptosis or even stimulate cell proliferation [25] . Combined radiotherapy and antiangiogenesis treatment could thus be expected to inhibit an HIF-1-induced angiogenic response.
Although modern technologies permit precise delivery of ionizing radiation to the tumor mass while minimizing exposure of surrounding healthy tissues, the efficacy of radiotherapy remains limited by the intrinsic or acquired radioresistance of many tumors. There is thus an ongoing search for agents that augment the sensitivity of tumor cells to radiation, with recent interest in targeting components of signaling pathways involved in tumor growth and radioresistance. In 1994, honokiol was first reported to have growth-inhibiting effects on human leukemic HL-60 cells [26] . The mechanism was proposed to be a nontoxic one. Honokiol was also found to be more effective in inducing apoptosis in SVR angiosarcoma cells [27] . Honokiol also has direct antiangiogenic activity, in that it blocks the phosphorylation and Rac activation due to VEGF-VEGF receptor 2 interactions. Honokiol has been shown to have both direct antiangiogenic and antitumor properties [27] . In a study of patients with chronic lymphocytic leukemia (CLL), honokiol had preferential activity against patientderived CLL cells versus normal lymphocytes [28] . Honokiol causes apoptosis in CLL cells through activation of caspase 8, followed by activation of caspase 9 and caspase 3 [28] . Studies indicated that irradiation induces the production of VEGF or platelet-derived growth factor, which are closely related to angiogenesis [29] . This may promote tumor regrowth after irradiation and result in protection of vessels from radiationinduced cell damage.
Radiotherapy is commonly used to treat local tumors to directly kill tumor cells. However, growth factors such as VEGF and FGF-2 are induced by tumor cells subsequent to radiation exposure [30] . This clearly points out that on exposure to low-dose radiation, the cells can adapt by enhancing radioresistance in both tumor cells and vascular endothelial cells by inducing angiogenesis growth factors, thereby inhibiting cell death by apoptosis [30] .
As mentioned above, honokiol can effectively inhibit the angiogenesis of different kinds of malignant tumors. The other point is that irradiation can induce the production of angiogenesis growth factors such as VEGF and FGF-2. Our previous studies showed that honokiol can effectively radiosensitize colon cancer cells. However, additional studies are required to determine whether honokiol increases the sensitivity of colon cancer cells to radiation through the suppression of the angiogenesis signaling pathway.
Honokiol and STAT3 Signaling
STAT3 mediates the expression of a variety of genes in response to cell stimuli, and thus plays a key role in many cellular processes, such as cell growth and apoptosis. STAT3 can promote oncogenesis by being constitutively active through various pathways. STAT3 activation has been closely linked with proliferation, survival, invasion, and angiogenesis of hepatocellular carcinoma and is an attractive target for therapy [5] . Rahaman et al. [31] have reported that inhibition of the STAT3 signaling pathway is associated with increased apoptosis and inhibition of proliferation in malignant glioma. Indeed, development of Akt and STAT3 inhibitors has been a major goal of pharmaceutical companies since the discovery that these pathways are often activated in numerous human cancers, such as melanoma, myeloma, brain cancer, breast cancers, and ovarian cancer.
The STAT3 signaling pathway plays a pivotal role in mediating extracellular stimuli and activating different oncogene factors. Janus kinase (Jak)/STAT pathways serve to block the apoptosis process, keeping cells alive in very toxic environments, such as chemotherapy or ionizing radiation [32, 33] . In the study by Sun et al. [34] , diindolylmethane was used to study the effect of STAT3 inhibition on human bladder cancer. It was found that different analogs of STAT3 were significantly inhibited by diindolylmethane, and that this obviously increased their radiosensitivity. This suggests that STAT3 signaling plays an important role in the mechanism of radioresistance of human bladder cancer cell lines. In the report by Lee et al. [35] on cucurbitacin's radiosensitivityenhancing effects on thyroid-cancer-derived CD133 + cells, the STAT3 signaling pathway was also highlighted. In another study by Sun et al. [36••] , TG101209, a small-molecule inhibitor of Jak2 (a STAT3-activating tyrosine kinase), was found to enhance the effects of radiation in lung cancer in vitro and in vivo. Pan et al. [37] reported that the STAT3 inhibiter Stattic significantly radiosensitizes nasopharyngeal carcinoma cells by inhibiting STAT3. In fact, Stattic selectively inhibits activation, dimerization, and nuclear translocation of STAT3 and decreases STAT3-mediated cyclin D1 expression. These data suggest that targeting STAT3 with chemotherapeutic agents may provide a new approach to increase the curative effect of radiotherapy.
Recent studies indicated that honokiol, as an effective chemotherapeutic agent, could effectively perform an antitumor function by inhibiting the STAT3 signaling pathway. Ishikawa et al. [38] found honokiol can induce cell cycle arrest and apoptosis via inhibition of survival signals in adult T-cell leukemia. It can suppress the phosphorylation and DNA binding of different oncogene factors such as nuclear factor kappa B, activator protein 1, STAT3, and STAT5. Yu et al. [39••] found that honokiol can cause necrosis and apoptosis in transformed Barrett's and esophageal adenocarcinoma cells through the inhibition of the STAT3 signaling pathway. Studies by Liu et al. [40] and Pan et al. [41] showed that honokiol can inhibit the growth and peritoneal metastasis of gastric cancer in nude mice, which was correlated with the inhibition of STAT3 signaling via the upregulation of Src homology 2 (SH2)-containing tyrosine phosphatase 1.
Taken together, these studies suggest that STAT3 signaling is closely related to radiosensitivity of many cancer cells.
Honokiol can clearly inhibit the STAT3 signaling pathway in different cancer cell lines. On the basis of these findings, we propose that honokiol may radiosensitize different cancer cell lines through inhibiting effects on the STAT3 signaling pathway. Further studies are essential to determine whether inhibiting STAT3 signaling is essential for honokiol function.
Notch-1 and Radiosensitization
Cancer stem cells (CSCs), or cancer-initiating cells, are believed to be responsible for tumor initiation. More importantly, there is a growing body of evidence suggesting that CSCs contribute to radioresistance [42••, 43, 44] . The relatively higher radioresistance of CSCs has been attributed to different intrinsic and extrinsic factors. Although the exact molecular mechanisms that control these processes remain unclear, three major signaling pathways (Notch, Hedgehog, and Wnt) have been identified to be highly active in CSCs, of which the Notch signaling pathway is probably the most important [44] .
Notch signaling plays a pivotal role in the regulation of many fundamental cellular processes. Accumulating data indicate that abnormal activation of the Notch gene is also involved in the genesis of almost all kinds of human cancers [45] . In addition, Notch is a critical pathway in CSC self-renewal and survival, whereas its inhibition was reported to deplete CSCs and inhibit tumor growth [46, 47] . Because of the abnormal activation of Notch signaling in variety of malignant tumors, this pathway is an attractive target for effective treatment. In our previous studies, we demonstrated that the combination of honokiol with radiation resulted in downregulation of the Notch ligand Jagged1 as well as all four essential members of the γ-secretase complex, the critical enzyme that cleaves and releases the intracellular domain from the membrane [7••] . Therefore, honokiol-and radiation-mediated inhibition of CRC cell growth is partly mediated via inactivation of Notch-1 activity. This is further supported by other studies with Notch inhibitors, which have significant antitumor effects [31, 48] . A number of agents, including γ-secretase inhibitors [35] , anti-Notch monoclonal antibodies, and RNA interference, have been demonstrated to effectively block the canonical Notch signaling pathway [49] .
Recent studies demonstrate Notch inhibitors can provide radiosensitization to different human cancers. They may perform this pivotal role through multiple mechanisms. One could be through targeting CSCs. A second method could be by blocking other key signaling pathways, thereby suppressing oncogene function, such as phosphatidylinositol 3-kinase/ Akt, p53, Ras, and mitogen-activated protein kinase kinase signaling [50, 51•, 52] . Further, Notch signaling can regulate expression of the Myc oncogene [53] , survivin [54] , and Bcl-2 and Bax [55] .
As we reported previously, honokiol can inhibit the Notch signaling pathway during the process of radiosensitizing colon cancer cells, and recent studies demonstrated Notch inhibitors can inhibit the proliferation and growth of many kinds of cancer cells by different signaling pathway. These findings suggest that honokiol may act as a radiosensitizer.
Honokiol and Mismatch Repair
DNA mismatch repair (MMR) is a highly conserved but complex system that ensures genomic stability on several levels, including correcting mismatches generated during DNA replication, blocking genetic recombination events between divergent DNA sequences, and mediating cell death in response to certain DNA-damaging agents. Importantly, MMR deficiency is associated with in vitro and in vivo "damage tolerance" (resistance) to multiple different classes of clinically active chemotherapy drugs as well as to other types of DNA damage (stress) agents, including ionizing radiation and hypoxia.
Recent studies revealed that different states of MMR lead to diverse responses to ionizing radiation. Yan et al. [56] demonstrated that colon cancer cells have greater radiosensitivity with enhanced expression of apoptotic and autophagic markers, more pronounced cell cycle alterations (increased late-S population and a G 2 /M arrest) following exposure to low-dose-rate ionizing radiation compared with isogenic cell lines lacking MLH1 [56] . In addition, while examining the radiosensitizing effect of gemcitabine (2′,2′-difluoro-2′-deoxycytidine) on different colon cancer cell lines, Robinson et al. [57] observed that only the MMR-deficient cell lines were radiosensitized. Furthermore, the data from this study showed the radiosensitizing effect has no relationship with the p53 pathway. In our previous study, we also observed that honokiol radiosensitizes MMR-deficient colon cancer cells. Together, these studies demonstrate that the MMR system plays an important role in the process of mediating radiosensitization.
Conclusion
A number of studies indicate that honokiol can inhibit proliferation and induce apoptosis. Recent studies have demonstrated the ability of honokiol to radiosensitize various types of cancers, including colon cancer [6••], lung cancer [58] , and ovarian and breast cancer [59] . These studies have also demonstrated that honokiol has the ability to radiosensitize cancers by inhibiting different pathways. Moreover, the radiosensitizing effects involved affecting both extrinsic and intrinsic pathways that affect cell cycle progression, tumor angiogenesis, the Jak/STAT3 signaling pathway, and the CSC-related Notch signaling pathway. Carcinogenesis is a very complicated process and many oncogenic signaling pathways are involved in this process [60] . As a neoadjuvant therapeutic approach, radiotherapy plays a pivotal role in the treatment of CRCs. We have determined that honokiol radiosensitizes colon cancer cells in an MMRdependent mechanism. However, how this pathway affects stemness is yet to be determined. As we continue to dissect the mechanism of honokiol, we hope to not only provide additional pathways affected by the compound but also to develop novel derivatives of the compound to further enhance the activity while reducing side effects, if any, from increasing dosing to pharmacological levels. 
